Our Team

Sekretariat:
Sina Vonhoegen
Tel.: 0241 80-89060
svonhoegenukaachende

A-G

Sevim Alkaya

Dr. Pia-Anita Antony, MD

Daniel Appel

Jonas Berger

Sarah Bringezu

Tabea Bunge

David Fiedler

Melanie Gajewski

Dr. Stefan Garczyk, PhD

Janina Gasthaus

Cordelia Geisler

Lukas Gola


H-K

Stefanie Ha

Dr. Alexander Hamm, MD

Kai Herbert Hänel

Matthias Heer

Caroline Heymann

Annika Honert

Dr. Laura Huth, PhD

Dr. Sebastian Huth, PhD

Stefan Thomas Kiesgen

Jennifer Kistermann

Oliver Klaas

Natalie Klotz

Maximilian Richard Karl-Georg Koch

Stefanie Köhler


L-S

Dr. Eva Lorsy, PhD

Lara Magnus

Dr. rer. nat. Jolein Mijnes, PhD

Dr. Erik Noetzel, PhD

Andrea Nülens

Maureen Onyuro

Dr. Martin Schlensog, PhD

Claudia Schubert

Carolin Schwenk

Dr. Esra Sevinc, MD

Philipp Stegen

Sabrina Szczepanski

Marta Szczygiel


T-W

Maximilian Tator

Dr. Anette ten Haaf, PhD

Janina Tiedemann

Aylin Emel Toktamis

Aylin Spohie Topuz

Dr. Jürgen Veeck, PhD

Lina Weber

Marc Wiesehöfer

Dr. Frank Wiesmann, PhD

Dr. Wiebke Inga Bente Winkens, MD


HYPMED project result presentation in Münster (Germany), June 2022:
From 09.06. to 11.06.2022, the annual meeting of the German Society of Pathology took place in Münster. As part of the AG Dahl working group, Lehr- und Forschungsgebiet Tumorpathologie, Ms Cosima Kunze, medical doctoral student, presented her project in an invited lecture entitled "Class II tumour suppressor genes in breast cancer can be classified according to intrinsic molecular subtypes and may be suitable for risk classification of ductal carcinoma in situ (DCIS)". In front of a large audience, Ms Kunze explained our hypothesis that class II tumour suppressor genes (C2TSGs) in breast cancer may be suitable for risk classification of early stages (ductal carcinoma in situ). These findings are a result of work package 4 in the EU-HYPMED project (http://www.hypmed.eu), which was worked on jointly by Prof. Wardelmann (Münster) and Prof. Dahl (Aachen). The team is pleased with the successful lecture of Ms. Kunze and hopes for future progress in risk classification of DCIS using this approach.